表紙
市場調査レポート

PharmaPoint:大腸がん - 世界の医薬品市場の2023年までの予測と市場分析

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 325931
出版日 ページ情報 英文 346 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
PharmaPoint:大腸がん - 世界の医薬品市場の2023年までの予測と市場分析 PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2023
出版日: 2014年11月30日 ページ情報: 英文 346 Pages
概要

大腸がん (結腸直腸がん:CRC) は、世界のがん患者の死亡原因の第2位に挙がっています。診断されたがんの中では、世界で3番目に多く、医療制度にとって莫大な負担となっています。

当レポートでは、世界の大腸がん (結腸直腸がん:CRC) の治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報 (製品説明、安全性、有効性) 、SWOT分析、売上高予測、影響分析 (動向、促進要因・抑制要因) などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
  • 臨床病期
  • 症状

第4章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界の動向
  • 予測手法
  • CRCの疫学予測
  • 議論

第5章 疾患の管理

  • 診断と治療の概要
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国

第6章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド

第7章 アンメットニーズと機会

  • 概要
  • 転移性患者の全生存率を実質的に高める治療
  • KRAS・BRAF変異陽性の患者に対する標的治療
  • 切除可能なハイリスク疾患に対する効果的なネオアジュバント/アジュバント療法
  • 化学療法抵抗性患者に対する許容できる後期治療

第8章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
  • 開発初期段階における有望なアプローチ

第9章 現在・将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル

第10章 市場の見通し

  • 世界市場
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国

第11章 付録

図表

目次
Product Code: GDHC95PIDR

Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended. The CRC market is expected to grow due to the incorporation of five late-stage pipeline agents during the forecast period, including Mologen's MGN1703, Eli Lilly's Cyramza, and Boehringer Ingelheim's nintedanib. Furthermore, GlobalData expects the label extension of Stivarga as a first-line adjuvant treatment for metastatic CRC patients with resected liver metastases. Ultimately, however, GlobalData expects unmet needs to remain unfulfilled by these pipeline agents, and anticipates that novel, innovative approaches, such as those targeting BRAF mutation-positive disease and immune checkpoint inhibitors, will provide the best opportunity for substantial improvement in the prognosis of advanced CRC patients.

Highlights

Key Questions Answered

  • What are the corporate strategies being used by drug makers?
  • How is the disease management evolving? What is the impact for drug manufacturers?
  • What opportunities remain after the launch of pipeline agents?
  • How large are the metastatic KRAS wild-type and mutation-positive CRC markets for branded agents, and which are growing the fastest?
  • What exciting, innovative approaches are being investigated in CRC? Which immunotherapies are of interest to the CRC market?
  • What do KOLs think about the latest therapies and drug development strategies?

Key Findings

  • By 2023, the end of the forecast period, GlobalData projects CRC sales to rise to $8.11 billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 4.9%. Major drivers of the growth of the CRC market over the forecast period include increasing CRC incident cases, the launch of premium-priced adjuvant and maintenance treatments for first-line metastatic disease, and the launch of pipeline agents for later-line CRC.
  • Roche's anti-angiogenesis drug Avastin has been the best-selling brand in CRC for many years, and, after label extension in the second-line continuation setting, is set to remain the market leader across the forecast period. However, competition in this drug class is expected to become more intense, especially in the second-line metastatic setting, as Sanofi/Regeneron's Zaltrap and Eli Lilly's pipeline agent Cyramza (ramucirumab) garner uptake across the major markets.
  • GlobalData expects the next surge of anti-angiogenesis drugs to be focused on the anti-Ang2 inhibitor class. This class is likely to be led by Roche's dual anti-VEGF/Ang2 inhibiting antibody vanucizumab (RO5520985; RG7221). Roche is currently investigating vanucizumab head-to-head against Avastin in a randomized Phase II study. If this agent is successful in a large, pivotal study, GlobalData anticipates vanucizumab to become a key part of Roche's strategy to overcome biosimilar erosion of Avastin towards the end of the forecast period.
  • Interviewed KOLs are enthusiastic about early-stage innovative approaches targeting metastatic CRC patients with BRAF and KRAS mutation-positive disease, and immune checkpoint inhibitors such as the anti-PD1/PDL1 drugs. With Big Pharma taking a leading role, GlobalData expects the targeted, biomarker-driven approach for the treatment of metastatic CRC to become a significant R&D strategy for developers during and beyond the forecast period.

Scope

  • Overview of colorectal cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized Colorectal cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns in eight patient segments, forecast from 2013 to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, remaining commercial opportunities, and current and future players for the colorectal cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global colorectal cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global colorectal cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global colorectal cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Clinical Staging
  • 3.3. Symptoms

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. 8MM, Incidence Trends
    • 4.3.2. 8MM, Five-Year Relative Survival
    • 4.3.3. 8MM, Screening Programs for CRC
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast of CRC (2013-2023)
    • 4.5.1. Diagnosed Incident Cases of CRC
    • 4.5.2. Age-Specific Diagnosed Incident Cases of CRC
    • 4.5.3. Sex-Specific Diagnosed Incident Cases of CRC
    • 4.5.4. Age-Standardized Incidence
    • 4.5.5. Cancer Stage at Diagnosis
    • 4.5.6. Diagnosed Five-Year Prevalent Cases of CRC
    • 4.5.7. KRAS Status among Diagnosed Five-Year Prevalent Cases of CRC
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Screening and Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
    • 5.2.1. Screening and Diagnosis
    • 5.2.2. Clinical Practice
  • 5.3. France
    • 5.3.1. Screening and Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Screening and Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Screening and Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Screening and Diagnosis
    • 5.6.2. Clinical Practice
  • 5.7. UK
    • 5.7.1. Screening and Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. Japan
    • 5.8.1. Screening and Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. China
    • 5.9.1. Screening and Diagnosis
    • 5.9.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Avastin (Bevacizumab)
    • 6.2.2. Erbitux (Cetuximab)
    • 6.2.3. Vectibix (Panitumumab)
    • 6.2.4. Stivarga (Regorafenib)
    • 6.2.5. Zaltrap (Ziv-Aflibrcept)
    • 6.2.6. Lonsurf (TAS-102)
    • 6.2.7. TS-1 (Tegafur, Gimeracil, Oteracil)
    • 6.2.8. Xeloda (Capecitabine)

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Cyramza (Ramucirumab)
    • 8.2.2. Imprime PGG
    • 8.2.3. MGN1703
    • 8.2.4. Nintedanib (BIBF-1120)
  • 8.3. Promising Approaches in Early-Stage Development
    • 8.3.1. Anti-Angiopoietin-2 Inhibitors
    • 8.3.2. Strategies for BRAF Mutation-Positive Disease
    • 8.3.3. Strategies for KRAS-Mutation Positive Disease
    • 8.3.4. Immune Checkpoint Inhibitors

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Roche/Genentech
    • 9.3.2. Sanofi
    • 9.3.3. Eli Lilly and Company
    • 9.3.4. Merck KGaA
    • 9.3.5. Bayer
    • 9.3.6. Taiho Pharmaceutical

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. China
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed Colorectal Cancer Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiration Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Average Body Weight and Surface Area Across the 8MM
    • 11.4.7. Individual Drug Assumptions
    • 11.4.8. Generic Erosion
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for this Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Epidemiologist
    • 11.7.3. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: TNM and Staging Classification System for CRC
  • Table 2: Symptoms of Colorectal Cancer
  • Table 3: Risk Factors and Comorbidities for CRC
  • Table 4: 8MM, Five-Year Relative Survival
  • Table 5: 8MM, Sources of CRC Incidence Data
  • Table 6: 8MM, Sources of CRC Diagnosed Five-Year Prevalent Cases Data
  • Table 7: 8MM, Sources of CRC Cancer Stage at Diagnosis Data
  • Table 8: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 9: 8MM, Age-Specific Diagnosed Incident Cases of CRC, Both Sexes, N, Row (%), 2013
  • Table 10: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, Ages ≥20 Years, 2013
  • Table 11: 8MM, Diagnosed Five-Year Prevalent Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 12: 8MM, KRAS Status among CRC Prevalent Cases, 2013
  • Table 13: Treatment Guidelines for CRC
  • Table 14: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013
  • Table 15: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013
  • Table 16: Country Profile - US
  • Table 17: Country Profile - France
  • Table 18: Country Profile - Germany
  • Table 19: Country Profile - Italy
  • Table 20: Country Profile - Spain
  • Table 21: Country Profile - UK
  • Table 22: Country Profile - Japan
  • Table 23: Country Profile - China
  • Table 24: Leading Treatments for CRC, 2014
  • Table 25: Product Profile - Avastin
  • Table 26: Avastin SWOT Analysis, 2014
  • Table 27: Global Sales Forecast ($m) for Avastin, 2013-2023
  • Table 28: Product Profile - Erbitux
  • Table 29: Erbitux SWOT Analysis, 2014
  • Table 30: Global Sales Forecast ($m) for Erbitux, 2013-2023
  • Table 31: Product Profile - Vectibix
  • Table 32: Vectibix SWOT Analysis, 2014
  • Table 33: Global Sales Forecast ($m) for Vectibix, 2013-2023
  • Table 34: Product Profile - Stivarga
  • Table 35: Stivarga SWOT Analysis, 2014
  • Table 36: Global Sales Forecasts ($m) for Stivarga, 2013-2023
  • Table 37: Product Profile - Zaltrap
  • Table 38: Zaltrap SWOT Analysis, 2014
  • Table 39: Global Sales Forecasts ($m) for Zaltrap, 2013-2023
  • Table 40: Product Profile - Lonsurf
  • Table 41: Lonsurf SWOT Analysis, 2014
  • Table 42: Global Sales Forecasts ($m) for Lonsurf (TAS-102), 2013-2023
  • Table 43: Product Profile - TS-1
  • Table 44: TS-1 SWOT Analysis, 2014
  • Table 45: Global Sales Forecasts ($m) for TS-1, 2013-2023
  • Table 46: Product Profile - Xeloda
  • Table 47: Unmet Need and Opportunity in CRC
  • Table 48: Product Profile - Cyramza
  • Table 49: Cyramza SWOT Analysis, 2014
  • Table 50: Global Sales Forecasts ($m) for Cyramza, 2013-2023
  • Table 51: Product Profile - Imprime PGG
  • Table 52: Imprime PGG SWOT Analysis, 2014
  • Table 53: Global Sales Forecasts ($m) for Imprime PGG, 2013-2023
  • Table 54: Product Profile - MGN1703
  • Table 55: MGN1703 SWOT Analysis, 2014
  • Table 56: Global Sales Forecasts ($m) for MGN1703, 2013-2023
  • Table 57: Product Profile - Nintedanib
  • Table 58: Nintedanib SWOT Analysis, 2014
  • Table 59: Global Sales Forecasts ($m) for Nintedanib, 2013-2023
  • Table 60: Anti-Angiopoietin-2 Inhibitors in Development
  • Table 61: Early-stage Strategies for BRAF Mutation-Positive CRC
  • Table 62: Early-stage Strategies for KRAS Mutation-Positive CRC
  • Table 63: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC
  • Table 64: Key Companies in the CRC Market in the 8MM, 2013-2023
  • Table 65: Roche's CRC Portfolio Assessment, 2014
  • Table 66: Sanofi's CRC Portfolio Assessment, 2014
  • Table 67: Eli Lilly's CRC Portfolio Assessment, 2014
  • Table 68: Merck KGaA's CRC Portfolio Assessment, 2014
  • Table 69: Bayer's CRC Portfolio Assessment, 2014
  • Table 70: Taiho's CRC Portfolio Assessment, 2014
  • Table 71: Sales Forecasts ($m) for Colorectal Cancer in the Global Markets, 2013-2023
  • Table 72: CRC Market Drivers and Barriers, 2014
  • Table 73: Sales Forecasts ($m) for Colorectal Cancer in the United States, 2013-2023
  • Table 74: Key Events Impacting Sales for CRC in the US, 2014
  • Table 75: US CRC Market Drivers and Barriers, 2014
  • Table 76: Sales Forecasts ($m) for Colorectal Cancer in France, 2013-2023
  • Table 77: Key Events Impacting Sales for CRC in France, 2014
  • Table 78: France CRC Market Drivers and Barriers, 2014
  • Table 79: Sales Forecasts ($m) for Colorectal Cancer in Germany, 2013-2023
  • Table 80: Key Events Impacting Sales for CRC in Germany, 2014
  • Table 81: Germany CRC Market Drivers and Barriers, 2014
  • Table 82: Sales Forecasts ($m) for Colorectal Cancer in Italy, 2013-2023
  • Table 83: Key Events Impacting Sales for CRC in Italy, 2014
  • Table 84: Italy CRC Market Drivers and Barriers, 2014
  • Table 85: Sales Forecasts ($m) for Colorectal Cancer in Spain, 2013-2023
  • Table 86: Key Events Impacting Sales for CRC in Spain, 2014
  • Table 87: Spain CRC Market Drivers and Barriers, 2014
  • Table 88: Sales Forecasts ($m) for Colorectal Cancer in the UK, 2013-2023
  • Table 89: Key Events Impacting Sales for CRC in the UK, 2014
  • Table 90: UK CRC Market - Drivers and Barriers, 2014
  • Table 91: Sales Forecasts ($m) for Colorectal Cancer in Japan, 2013-2023
  • Table 92: Key Events Impacting Sales for CRC in Japan, 2014
  • Table 93: Japan CRC Market - Drivers and Barriers, 2014
  • Table 94: Sales Forecasts ($m) for Colorectal Cancer in China, 2013-2023
  • Table 95: Key Events Impacting Sales for CRC in China, 2014
  • Table 96: China CRC Market - Drivers and Barriers, 2014
  • Table 97: Key Launch Dates
  • Table 98: Key Patent Expiries
  • Table 99: Average Body Weight and Surface Area Across the 8MM
  • Table 100: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Historical Age-Adjusted CRC Incidence (Cases per 100,000 Population) in 8MM, Men, 1998-2007
  • Figure 2: Historical Age-Adjusted CRC Incidence (Cases per 100,000 Population), in 8MM, Women, 1998-2007
  • Figure 3: 8MM, Diagnosed Incident Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC, Both Sexes, N, 2013
  • Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, Ages ≥20 Years, 2013
  • Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013.
  • Figure 7: 8MM, Cancer Stage at Diagnosis Percentage Distribution, Ages ≥20 Years.
  • Figure 8: 8MM, Diagnosed Five-Year Prevalent Cases of CRC, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 9: CRC - Phase III Pipeline
  • Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2013-2023
  • Figure 11: Clinical and Commercial Positioning of Cyramza
  • Figure 12: Clinical and Commercial Positioning of Imprime PGG
  • Figure 13: Clinical and Commercial Positioning of MGN1703
  • Figure 14: Clinical and Commercial Positioning of Nintedanib
  • Figure 15: Global Sales of Branded Products for Colorectal Cancer by Company, 2013-2023
  • Figure 16: Company Portfolio Gap Analysis in CRC, 2013-2023
  • Figure 17: Roche SWOT Analysis in CRC, 2014
  • Figure 18: Sanofi SWOT Analysis in CRC, 2014
  • Figure 19: Eli Lilly SWOT Analysis in CRC, 2014
  • Figure 20: Merck KGaA SWOT Analysis in CRC, 2014
  • Figure 21: Bayer SWOT Analysis in CRC, 2014
  • Figure 22: Taiho SWOT Analysis in CRC, 2014
  • Figure 23: Global Sales for Colorectal Cancer by Region, 2013-2023
  • Figure 24: Sales for Colorectal Cancer in the United States by Drug Class, 2013-2023
  • Figure 25: Sales for Colorectal Cancer in France by Drug Class, 2013-2023
  • Figure 26: Sales for Colorectal Cancer in Germany by Drug Class, 2013-2023
  • Figure 27: Sales for Colorectal Cancer in Italy by Drug Class, 2013-2023
  • Figure 28: Sales for Colorectal Cancer in Spain by Drug Class, 2013-2023
  • Figure 29: Sales for Colorectal Cancer in the United Kingdom by Drug Class, 2013-2023
  • Figure 30: Sales for Colorectal Cancer in Japan by Drug Class, 2013-2023
  • Figure 31: Sales for Colorectal Cancer in China by Drug Class, 2013-2023
Back to Top